LY9 and plasma cell myeloma: recently published a novel approach whereby the affinity of the anti-CD229 target-binding domain was slightly reduced, which, in conjunction with modifying the CAR construct to over-express the transcription factor c-Jun, generated CAR T cells with a favorable immunophenotype that targeted myeloma cells but spared healthy unmodified lymphocytes (123).